Salute e Benessere

Oclean: Women vs. Men - Oral Hygiene Research Report

Women Are More Systematic Women Are More Systematic Women are less likely to forget to brush their teeth—only 33% admitted that they occasionally skip this ritual in the evening, and 22% forget to do it in the morning. Among men, these values are significantly higher—45% forget to brush their teeth before bed, and 37% skip it in the morning. This regularity is also evident in how often they replace their toothbrush or sonic brush head—65% of women do so every three months, compared to only...
PR Newswire
07/03/2025

Orphalan becomes the first European company to enter in China's Wilson Disease…

This launch is made possible through a strategic partnership with SPH Kyuan Trade, a leading pharmaceutical distributor in China and a subsidiary of Shanghai Pharma Group, one of the country's largest healthcare conglomerates. Together, Orphalan and SPH Kyuan Trade will work to dramatically expand patient access to this critical treatment. This launch is made possible through astrategic partnership with SPH Kyuan Trade, a leading pharmaceutical distributor inChinaand a subsidiary of...
PR Newswire
07/03/2025

Feminine Intimate Care Market to Reach $14 billion, Globally, by 2034 at 6.1%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A291929 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A291929 Prime determinants of growth Growing disposable incomes, knowledge of personal cleanliness, and the desire for organic and natural products are the main factors propelling the market for feminine intimate care. Women's adoption of improved hygienic habits and the move toward...
PR Newswire
07/03/2025

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for…

COPENHAGEN, Denmark, March 7, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization application and accepted to start the review of the Company's single-dose chikungunya vaccine, CHIKV VLP vaccine, for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.The application was submitted to MHRA in February 2025 under the...
Nasdaq GlobeNewswire
07/03/2025

Roche announces launch of Roche Genentech Innovation Center Boston based at…

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and developmentRoche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the project's cutting-edge lab spaceStarting with a lease of 30'000 square feet, Roche intends to invest over the coming years into a...
Nasdaq GlobeNewswire
07/03/2025

Global Interventional Neuroradiology Market to Cross USD 50 Billion by 2032 |…

Key Takeaways from the Interventional Neuroradiology Market Report Key Takeaways from the Interventional Neuroradiology Market Report To read more about the latest highlights related to the interventional neuroradiology market, get a snapshot of the key highlights entailed in the Global Interventional Neuroradiology Market Report Interventional Neuroradiology Overview Interventional neuroradiology (INR), also known as neurointerventional surgery, is a specialized field of...
PR Newswire
06/03/2025

TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping…

EMD Serono's TEPMETKO (tepotinib) Overview EMD Serono's TEPMETKO (tepotinib) Overview TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as hydrochloride monohydrate), administered orally. Patients should be cautioned about the heightened risk of severe or fatal interstitial lung disease/pneumonitis, liver toxicity, and potential embryo-fetal toxicity,...
PR Newswire
06/03/2025

HAVAS HEALTH NETWORK LAUNCHES ITS GLP-1 CONSULTANCY IN PARIS WITH "SHAPE…

Positioned at the nexus of health, creativity, and technology, this initiative underscores Havas' commitment to innovation, offering unique first mover thinking to clients, industry partners, and brand marketers navigating the rapidly growing GLP-1 space. Positioned at the nexus of health, creativity, and technology, this initiative underscores Havas' commitment to innovation, offering unique first mover thinking to clients, industry partners, and brand marketers navigating the rapidly…
PR Newswire
06/03/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 02/28/2025100,093,87388,849,752For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
06/03/2025

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial…

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 –– VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma –– Received guidance from the FDA and EMA on Phase 3 pivotal trial design for VCN-01 in combination with standard-of-care chemotherapy for metastatic PDAC ––– As of December 31,...
Nasdaq GlobeNewswire
06/03/2025

Ipsen - February 2025 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 28 February 202583,814,526Gross...
Nasdaq GlobeNewswire
06/03/2025

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the…

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO onLusvertikimab and the Future of IBDNANTES, France – March 6, 2025, 6:00pm CET- OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs) to discuss the latest clinical trial results and scientific data on Lusvertikimab, particularly its positive outcomes in treating ulcerative colitis (UC).The webinar included insights from:Prof Laurent Peyrin-Biroulet, Professor of Gastroenterology, Nancy...
Nasdaq GlobeNewswire
06/03/2025

Microplates Market to Reach USD 1,301.08 million by 2032, Growing at an 4.50%…

Browse the report and understand how it can benefit your business strategy –https://www.credenceresearch.com/report/microplates-market Browse the report and understand how it can benefit your business strategy – https://www.credenceresearch.com/report/microplates-market Key Growth Determinants Rising Adoption of High-Throughput Screening (HTS) in Drug Discovery The increasing use of high-throughput screening (HTS) in pharmaceutical and biotechnology research is a significant...
PR Newswire
06/03/2025

Molecular Spectroscopy Market Size Booms with CAGR 4.9% and Projected to Reach…

The Molecular Spectroscopy Market Report provides valuable insights that help market players identify emerging trends, opportunities, and competitive dynamics. It offers data on market size, growth forecasts, and regional demand, allowing companies to plan effectively. The report also highlights technological advancements, regulatory landscapes, and consumer behavior, enabling players to stay ahead of the curve. By understanding these factors, businesses can make informed decisions on product…
PR Newswire
06/03/2025

Orthopedic Devices Market worth US$68.51 billion by 2030 with 4.8% CAGR |…

Browse in-depth TOC on "Orthopedic Devices Market" Browse in-depth TOC on "Orthopedic Devices Market" 300 - Tables50 - Figures450 - Pages By Based on the site,the global orthopedic devices market is segmented, the orthopedic devices market is divided into hand and wrist, spine, foot and ankle, arms and elbow, knee and thigh, hip and pelvis, shoulder, and craniomaxillofacial. The foot & ankle segment to register significant growth over the forecast period. The...
PR Newswire
06/03/2025

Industrial Gearbox Market to Reach USD 37.1 Billion by 2029 | Key Trends &…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27A15931/Global_and_India_Industrial_Gearbox_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-27A15931/Global_and_India_Industrial_Gearbox_Market Major Factors Driving the Growth of Industrial Gearbox Market : The industrial gearbox market is witnessing robust expansion driven by increasing demand for reliable power transmission solutions across various industrial...
PR Newswire
06/03/2025

NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting…

Company announcement no. 3-256 March 2025 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2025 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Friday, 28 March 2025, at 14:00 (CET) at Glostrup Park Hotel, Hovedvejen 41, 2600 Glostrup, Denmark. The notice to convene the Annual General Meeting including Appendix 1 is attached. Additional information For additional information, please contact: Sebastian Rosborg,Head of...
Nasdaq GlobeNewswire
06/03/2025

Vitestro Unveils Aletta™: The World's First Autonomous Robotic Phlebotomy…

"The name Aletta fosters a human connection with both healthcare professionals and patients—making Aletta more than just technology," says Brian Joseph, Co-Founder and Commercial Director at Vitestro. Patients and healthcare staff will interact with Aletta every day, and we want them to see her as an integral part of the phlebotomy team. By working alongside trained medical personnel, Aletta enhances precision and efficiency, ensuring a seamless experience and the highest quality of…
PR Newswire
06/03/2025

Elsevier Health launches HESI Clinical Practice Readiness Assessment (CPRA): the…

NEW YORK, March 6, 2025 /PRNewswire/ -- Elsevier Health, a global leader in medical information and data analytics, today launched HESI Clinical Practice Readiness Assessment (CPRA), the first standardized, objective, and reliable assessment for faculty to assess nursing students' clinical judgment and practice readiness. NEW YORK , March 6, 2025 /PRNewswire/ -- Elsevier Health, a global leader in medical information and data analytics, today launched HESI Clinical Practice Readiness...
PR Newswire
06/03/2025

Evolution Optiks Expands IP Portfolio with Two Key U.S. Patents for Light Field…

"These latest additions to our broad IP portfolio underline our innovative force and boost our position as a global leader in light field technology and its multi-faceted applications, well beyond vision care. Our mission is to not only revolutionize eye care, but ultimately, to redefine how artificial light is created and perceived. Imagine your iPhone or your car dashboard automatically adjusting to your eyesight, with no need for reading glasses. This, and more, is made possible by our…
PR Newswire
06/03/2025

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.Please read the full announcement in PDF. Attachment 2025_09_Trading_By_Management
Nasdaq GlobeNewswire
06/03/2025

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a…

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a.177 Lu-edotreotide v. 14.1 months on everolimus; p value=0.022Company plans for U.S. New Drug Application (NDA) submission in 2025Krakow, PolandMarch 6, 2025-ITM Isotope Technologies Munich SE(ITM), a leading radiopharmaceutical biotech company, today presented positive topline data...
Nasdaq GlobeNewswire
06/03/2025

Top-rated US health system expands Sectra's enterprise imaging solution with…

"Unifying different medical specialties in the same platform leads to several advantages, but above all it fosters collaboration between specialties around patient cases, so-called integrated diagnostics. This is particularly beneficial in cancer care. By taking this step, this healthcare provider demonstrates a strong commitment to advancing cancer diagnostics, and we are excited to support them on this journey," says Isaac Zaworski, President of Sectra Inc. "Unifying different…
PR Newswire
06/03/2025

Coway to Showcase its Water Purifier Expertise at Aquatech Amsterdam 2025

At the exhibition, Coway will explore new growth opportunities in the European water purifier market, by forging new partnerships and enhancing its brand awareness. Alongside its highly successful Asian product lineup, Coway is also set to introduce products optimized for European customers and businesses. At the exhibition, Coway will explore new growth opportunities in the European water purifier market, by forging new partnerships and enhancing its brand awareness. Alongside its highly...
PR Newswire
06/03/2025
Altri  Comunicati